Touch-down reverse transcriptase-PCR detection of IgV(H) rearrangement and Sybr-Green-based real-time RT-PCR quantitation of minimal residual disease in patients with chronic lymphocytic leukemia
Language English Country United States Media print
Document type Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
16035732
DOI
10.2165/00066982-200509010-00004
PII: 914
Knihovny.cz E-resources
- MeSH
- Benzothiazoles MeSH
- Quinolines MeSH
- Leukemia, Lymphocytic, Chronic, B-Cell diagnosis MeSH
- Diamines MeSH
- Humans MeSH
- Organic Chemicals analysis chemistry MeSH
- Reverse Transcriptase Polymerase Chain Reaction methods MeSH
- Gene Rearrangement, B-Lymphocyte, Heavy Chain genetics MeSH
- Neoplasm, Residual MeSH
- RNA, Neoplasm analysis chemistry MeSH
- Sensitivity and Specificity MeSH
- Immunoglobulin Heavy Chains genetics MeSH
- Immunoglobulin Variable Region genetics MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Evaluation Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Benzothiazoles MeSH
- Quinolines MeSH
- Diamines MeSH
- Organic Chemicals MeSH
- RNA, Neoplasm MeSH
- SYBR Green I MeSH Browser
- Immunoglobulin Heavy Chains MeSH
- Immunoglobulin Variable Region MeSH
BACKGROUND: Patients with chronic lymphocytic leukemia (CLL) can relapse even after aggressive therapy and autografts. It is commonly assumed that to prevent relapse the level of minimal residual disease (MRD) should be as low as possible. To evaluate MRD, highly sensitive quantitative assays are needed. AIM: The aim of the study was to develop a robust and sensitive method for detection of the clonal immunoglobulin heavy-chain variable (IgV(H)) rearrangement in CLL and to introduce a highly sensitive and specific methodology for MRD monitoring in patients with CLL who undergo intensive treatment. METHODS: As a prerequisite for MRD detection, touch-down reverse transcriptase (RT)-PCR using degenerate primers were used for the diagnostic identification of (H) gene rearrangement(s). For quantitative MRD detection in 18 patients, we employed a real-time RT-PCR assay (RQ-PCR) making use of patient-specific primers and the cost-saving Sybr-Green reporter dye (SG). For precise calibration of RQ-PCR, patient-specific IgV(H) sequences were cloned. RESULTS: Touch-down RT-PCR with degenerate primers allowed the successful detection of IgV(H) clonal rearrangement(s) in 252 of 257 (98.1%) diagnostic samples. Biallelic rearrangements were found in 27 of 252 (10.7%) cases. Degenerate primers used for the identification of clonal expansion at diagnosis were not sensitive enough for MRD detection. In contrast, our RQ-PCR assay using patient-specific primers and SG reached the sensitivity of 10(-)(6). We demonstrated MRD in each patient tested, including four of four patients in complete remission following autologous hematopoietic stem cell transplantation (HSCT) and three of three following allogeneic 'mini'-HSCT. Increments in MRD might herald relapse; aggressive chemotherapy could induce molecular remission. CONCLUSIONS: Our touch-down RT-PCR has higher efficiency to detect clonal IgV(H) rearrangements including the biallelic ones. MRD quantitation of IgV(H) expression using SG-based RQ-PCR represents a highly specific, sensitive, and economic alternative to the current quantitative methods.
See more in PubMed
Leukemia. 2000 Feb;14(2):324-8 PubMed
Blood. 2001 Apr 1;97(7):1929-36 PubMed
Ann Oncol. 2000;11 Suppl 3:197-8 PubMed
Arthritis Res. 2000;2(4):303-14 PubMed
J Exp Med. 2001 Dec 3;194(11):1625-38 PubMed
Blood. 1998 Feb 1;91(3):756-63 PubMed
Semin Hematol. 2004 Jul;41(3):207-23 PubMed
Blood. 1999 Sep 15;94(6):1840-7 PubMed
Blood. 2002 Jul 15;100(2):635-9 PubMed
N Engl J Med. 1995 Oct 19;333(16):1052-7 PubMed
Hematol Cell Ther. 1999 Feb;41(1):13-8 PubMed
Leukemia. 2001 Jul;15(7):1072-80 PubMed
Leukemia. 1997 Oct;11(10):1793-8 PubMed
Blood. 2004 Oct 15;104(8):2600-2 PubMed
N Engl J Med. 2000 Dec 28;343(26):1910-6 PubMed
Semin Hematol. 2004 Jul;41(3):246-53 PubMed
Hematology Am Soc Hematol Educ Program. 2001;:140-56 PubMed
Cancer. 1981 Jul 1;48(1):198-206 PubMed
J Exp Med. 1997 Apr 21;185(8):1435-45 PubMed
Haematologica. 1995 Mar-Apr;80(2):176-93 PubMed
Blood. 1975 Aug;46(2):219-34 PubMed
Blood. 2002 Aug 15;100(4):1410-6 PubMed
Blood. 1996 Jun 15;87(12):4990-7 PubMed
Acta Haematol. 2004;112(1-2):111-9 PubMed
Leukemia. 2002 Jun;16(6):993-1007 PubMed
J Pathol. 1993 Mar;169(3):291-5 PubMed
Leukemia. 2002 Jun;16(6):985-92 PubMed
Blood. 2003 Mar 1;101(5):2049-53 PubMed
Br J Haematol. 1990 Jun;75(2):163-7 PubMed
Ann Hematol. 2002 May;81(5):258-66 PubMed
Med Clin North Am. 1984 May;68(3):697-711 PubMed
Leuk Lymphoma. 2001 Aug;42(4):747-56 PubMed
Haematologica. 2001 Aug;86(8):827-36 PubMed
Leukemia. 2000 Apr;14(4):754-66 PubMed
J Clin Invest. 1998 Oct 15;102(8):1515-25 PubMed
Semin Oncol. 2000 Oct;27(5):587-97 PubMed
Leukemia. 1997 Nov;11(11):1909-14 PubMed
Blood. 1991 Oct 15;78(8):1901-14 PubMed
Blood. 1999 Sep 15;94(6):1848-54 PubMed
